Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 1/20 | 0.57 |
| ▸ | ARG2 | P78540 | 4/20 | 0.52 |
| ▸ | ARG1 | P05089 | 3/20 | 0.52 |
| ▸ | NOS2 | P35228 | 5/20 | 0.50 |
| ▸ | NOS1 | P29475 | 4/20 | 0.50 |
| ▸ | NOS3 | P29474 | 3/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.49 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | OTC | P00480 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL64149 | 1.00 | GSR (0.57) | GSRARG2ARG1NOS2NOS1 | |
| SCHEMBL623369 | 1.00 | GSR (0.57) | GSRARG2ARG1NOS2NOS1 | |
| SCHEMBL6369985 | 0.98 | GSR (0.55) | GSRARG2ARG1NOS2NOS1 | |
| SCHEMBL28449339 | 0.98 | GSR (0.55) | GSRARG2ARG1NOS2NOS1 | |
| SCHEMBL25670261 | 0.98 | GSR (0.55) | GSRARG2ARG1NOS2NOS1 | |
| Hydrochloric Acid SCHEMBL5971277 | 0.98 | GSR (0.55) | GSRARG2ARG1NOS2NOS1 | |
| Hydrochloric Acid SCHEMBL8919761 | 0.98 | GSR (0.55) | GSRARG2ARG1NOS2NOS1 | |
| Hydrochloric Acid SCHEMBL27243097 | 0.98 | GSR (0.55) | GSRARG2ARG1NOS2NOS1 | |
| SCHEMBL3438660 | 0.94 | GSR (0.54) | GSRARG2ARG1NOS2NOS1 | |
| SCHEMBL31688818 | 0.94 | GSR (0.54) | GSRARG2ARG1NOS2NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 334 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12584924-B2 | Compositions and methods for diagnosing and treating chronic kidney disease | SOCIETE DES PRODUITS NESTLE S.A. (CH) | 2026-03-24 | — | — | US | claimed |
| WO-2025123045-A1 | PREDICTIVE AND DIAGNOSTIC SCREENING METHODS FOR ENDOMETRIAL CANCER | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2025-06-12 | — | — | WO | claimed |
| CN-119555942-A | Fecal metabolite combination for auxiliary diagnosis of subclinical mastitis of dairy cows and application thereof | 武汉市农业科学院 | 2025-03-04 | — | — | CN | claimed |
| US-12180249-B1 | Compositions and methods for selective labeling of secondary amines | EMORY UNIVERSITY (US) | 2024-12-31 | — | — | US | claimed |
| EP-4457513-A1 | COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING CHRONIC KIDNEY DISEASE | Société des Produits Nestlé S.A. (CH) | 2024-11-06 | — | — | EP | claimed |
| US-20240260865-A1 | METHOD OF PRODUCING THIN ENZYME-BASED SENSING LAYERS ON PLANAR SENSORS | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2024-08-08 | — | — | US | claimed |
| CN-118435054-A | Compositions and methods for diagnosing and treating chronic kidney disease | 雀巢产品有限公司 | 2024-08-02 | — | — | CN | claimed |
| US-20240197662-A1 | METHODS OF AND COMPOSITIONS FOR TREATING OBESITY, OBESITY-RELATED DISEASES OR CANCERS USING A N6-METHYLLYSINE/L-LYSINE MIXTURE | TAINNOVATION INC. | 2024-06-20 | — | — | US | claimed |
| US-11969246-B2 | Method of producing thin enzyme-based sensing layers on planar sensors | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2024-04-30 | — | — | US | claimed |
| US-20230390346-A1 | PROBIOTIC BACILLUS COMPOSITIONS AND METHODS OF USE | BIOMEDIT, LLC | 2023-12-07 | — | — | US | claimed |
| US-20230204604-A1 | COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING CHRONIC KIDNEY DISEASE | SOCIETE DES PRODUITS NESTLE S.A. (CH) | 2023-06-29 | — | — | US | claimed |
| EP-4176050-A1 | PYRROLYSYL-TRNA SYNTHETASE VARIANTS AND USES THEREOF | enGenes Biotech GmbH (AT) | 2023-05-10 | — | — | EP | claimed |
| WO-2022067052-A1 | PROBIOTIC BACILLUS COMPOSITIONS AND METHODS OF USE | ELANCO US INC. (US) | 2022-03-31 | — | — | WO | claimed |
| WO-2022003142-A1 | PYRROLYSYL-tRNA SYNTHETASE VARIANTS AND USES THEREOF | ENGENES BIOTECH GMBH (AT) | 2022-01-06 | — | — | WO | claimed |
| US-9101662-B2 | Compositions with modulating agents | FOAMIX PHARMACEUTICALS LTD. (IL) | 2015-08-11 | — | — | US | claimed |
| US-8795693-B2 | Compositions with modulating agents | FOAMIX LTD. (IL) | 2014-08-05 | — | — | US | claimed |
| CN-103534265-A | Cyclic peptides with an anti-neoplasic and anti-angiogenic activity | CT INGENIERIA GENETICA BIOTECH | 2014-01-22 | — | — | CN | claimed |
| EP-2097065-A2 | FOAMABLE WATERLESS COMPOSITIONS WITH MODULATING AGENTS | Foamix Ltd. (IL) | 2009-09-09 | — | — | EP | claimed |
| WO-2008152444-A2 | FOAMABLE WATERLESS COMPOSITIONS WITH MODULATING AGENTS | FOAMIX LTD. (US) | 2008-12-18 | — | — | WO | claimed |
| US-20080206159-A1 | Drug mixture contains solvents, nonionic surfactants, gelling agent, therapeutic active agent, liquefied or compressed gas propellant; pressurized dispenser; treating skin diseases, dermal and mucosal delivery; stable and non-irritating emulsions | FOAMIX LTD. (IL) | 2008-08-28 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080206159-A1 | Drug mixture contains solvents, nonionic surfactants, gelling agent, therapeutic active agent, liquefied or compressed gas propellant; pressurized dispenser; treating skin diseases, dermal and mucosal delivery; stable and non-irritating emulsions | CUTA, SLTM, SMO | GSR 355/4885ARG2 4296/4885ARG1 4062/4885 |
| US-12180249-B1 | Compositions and methods for selective labeling of secondary amines | ADAR, RNMT, ALKBH1 | GSR 3475/4885ARG2 269/4885ARG1 284/4885 |
| US-12584924-B2 | Compositions and methods for diagnosing and treating chronic kidney disease | GLS, AADAT, FGF23 | GSR 2589/4885ARG2 39/4885ARG1 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.